NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies of NVC-422, an Aganocide(R) compound.

Presentation details are as follows:

Poster Title: N,N-dichloro-2,2-dimethyltaurine (NVC-422) has bactericidal activity against antiseptic and antibiotic-resistant Staphylococcus aureus Date/Time: Monday September 14, from 11:15 am to 1:15 pm (Pacific Time) Session: 163. Miscellaneous Abstract Number: E-1468 Location: Hall B Poster Title: Antimicrobial activity of endogenous and stabilized derivatives of N-chlorotaurines against representative microorganisms in the presence of human plasma, serum and albumin Date/Time: Monday September 14, from 11:15 am to 1:15 pm (Pacific Time) Session: 167-New Topical Antibacterial Agents Including Agents against C. difficile Abstract Number: F1-1526 Location: Hall B

"These findings support the compelling therapeutic profile of NVC-422 as a broad spectrum antimicrobial agent that carries little potential for resistance through common antiseptic resistance mechanisms," said Dr. Dmitri Debabov, poster co-author and assistant director of microbiology and acting head of biology of NovaBay Pharmaceuticals.

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. In preclinical trials, the Aganocide compounds have shown to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.